Takeda pays $35 million for Colo. vaccine developer

05/8/2013 | Denver Post, The

Takeda Pharmaceutical, through Takeda America Holdings, agreed to acquire Inviragen for $35 million in cash plus $215 million in potential milestone fees contingent on the progress of the firm's infectious-disease vaccines. Inviragen is developing vaccines for dengue as well as hand, foot and mouth disease.

View Full Article in:

Denver Post, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI